Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 29,036 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disease;Neurological Clear all

Conditions: Problem Behavior, Developmental Delay, Developmental Disability
Interventions: Function-based assessment and intervention; Behavioral
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 0 Months to 5 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Agitation, Dementia
Interventions: BXCL501, Matching Placebo; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 65 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 11
States / cities: Phoenix, Arizona • Long Beach, California • Daytona Beach, Florida + 8 more

Conditions: Alzheimer Disease
Interventions: RB-ADSC; Biological
Lead sponsor: Regeneration Biomedical, Inc.; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Acute on Chronic Liver Failure (ACLF), Hepatic Encephalopathy (HE)
Interventions: metra® Extracorporeal Liver Cross-Circulation (ELC) system (OrganOx), EGEN-5784 (genetically engineered porcine liver); Device · Biological
Lead sponsor: eGenesis, INC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: St Louis, Missouri • Madison, Wisconsin

Conditions: Migraine
Interventions: Nerivio; Device
Lead sponsor: Theranica; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: PARKINSON DISEASE (Disorder)
Interventions: Transcranial Electrical Stimulation Device; Device
Lead sponsor: U: The Mind Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ischemic Optic Neuropathy
Interventions: VEP under TIVA, VEP under balanced anesth., Propofol, Desflurane; Device · Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cervicogenic Headache, Occipital Neuralgia
Interventions: SPRINT Peripheral Nerve Stimulation (PNS) System; Device
Lead sponsor: SPR Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Santa Rosa, California • Waltham, Massachusetts • Rochester, Minnesota + 7 more

Conditions: Migraine Disease, Patent Foramen Ovale
Interventions: Prasugrel 5mg, Transcatheter Closure of Patent Foramen Ovale; Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Hemiparesis
Interventions: Axem Home; Device
Lead sponsor: Axem Neurotechnology Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions: KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen; Biological · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Atrial Fibrillation, Ischemic Stroke
Interventions: Atrial fibrillation risk electronic health record alert; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Duchenne Muscular Dystrophy
Interventions: PF-06252616, Placebo; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 15 Years · Male only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 14 more

Conditions: Multiple Sclerosis
Interventions: progressive resistance training; Behavioral
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 21 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease
Interventions: ADS-5102, Placebo; Drug · Other
Lead sponsor: Adamas Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 37 more

Conditions: Stroke, Parkinson's Disease, Muscle Weakness
Interventions: Canine Animal-Assisted Therapy, Standard of Care Physical Therapy; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Musculoskeletal Pain
Interventions: Video, Phone follow-up; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Ischemic Stroke, Systemic Embolism
Interventions: AtriClip LAA Exclusion System; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6,573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 102
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 81 more

Conditions: Spinal Cord Injury, Cerebral Palsy, Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: Lee Blonder; Other
Eligibility: 40 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Argininosuccinate Lyase Deficiency, Urea Cycle Disorder, Urea Cycle Disorders, Inborn, Argininosuccinic Aciduria
Interventions: Neo-ASA, Placebo; Dietary Supplement
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 6 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Williams Syndrome, Supravalvular Aortic Stenosis, Cardiovascular Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 3 Years to 85 Years
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2024
U.S. locations: 2
States / cities: Bethesda, Maryland • St Louis, Missouri

Conditions: Sleep Apnea, Obstructive
Interventions: Under-mattress sleep monitor; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 22 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Inherited Mitochondrial Disease
Interventions: Vatiquinone; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: Not listed
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 14
States / cities: La Jolla, California • Stanford, California • New Haven, Connecticut + 10 more

Search by objective public record fields.

Problem Behavior Assessment and Intervention in IDEA Part C Services

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease

RENEW: Study of Porcine Liver Support in Participants With Acute-on-Chronic Liver Failure

Real-World Evidence (RWE) Data Analysis of 1-year Consecutive Use of Remote Electrical Neuromodulation (REN)

Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms

Safety and Efficacy of Using SightSaver Visual Evoked Potential (VEP) for VEP Monitoring in Prone Spine Surgery

The MONARCH Case Series Study: SPRINT® Peripheral Nerve Stimulation for the Treatment of Head Pain

Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy

Post-stroke Motor Rehabilitation Using Functional Near-infrared Spectroscopy-based Brain-computer-interface

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Precision Medicine in Ischemic Stroke and Atrial Fibrillation

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy

Evaluating Intervention Responsiveness in People With Multiple Sclerosis

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)

Inpatient Physical Activity Function Through Enhanced Participation Levels in Animal-Assisted Therapy Programs

Patient Education to Improve Pain Management in Older Adults With Acute Musculoskeletal Pain: A Pilot Randomized Trial

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Experimental Evaluation of Wheelchair-Mounted Robotic Arms

Neuroimaging Studies of Depression in Parkinson's Disease

Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD

Impact of Elastin Mediated Vascular Stiffness on End Organs

Evaluating an Under-mattress Sleep Monitor Compared to a Peripheral Arterial Tonometry Device in the Diagnosis of Obstructive Sleep Apnea

A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease